MedTrace Logo

Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure

NCT03273322 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2021-12-21

No results posted yet for this study

Summary

Evaluation of 2 doses of rivaroxaban (10 and 15 mg) compared to dual anti platelet therapy (aspirin+clopidogrel) after left atrial appendage closure. The patients will be assessed at 10 and 90 days: central laboratory hemostasis analysis and clinical events assessment.

Conditions

Interventions

DRUG

Rivaroxaban 10 mg qd

10mg qd

DRUG

Rivaroxaban 15 mg qd

15mg qd

DRUG

DAPT

Aspirin 75 mg qd + Clopidogrel 75 mg qd

Sponsors & Collaborators

  • Action Research Group

    collaborator OTHER

  • Bayer

    collaborator INDUSTRY

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Gilles MONTALESCOT, MD, PhD · Centre Hospitalier Universitaire Pitié-Salpêtrière Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-13
Primary Completion
2018-11-20
Completion
2019-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03273322 on ClinicalTrials.gov